title: Müllerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis.
abstract: OBJECTIVE
  To determine Müllerian inhibiting substance (MIS) levels in follicular fluid (FF) and sera of IVF patients.
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  Fertility center.
  
  
  METHODS
  Sixty-six patients: 20 with tubal factor infertility, 17 with polycystic ovary syndrome (PCOS), and 29 with endometriosis.
  
  
  METHODS
  All patients underwent ovarian stimulation with hMG and/or FSH, as well as oocyte retrieval for IVF.
  
  
  METHODS
  Follicular fluid and serum MIS levels and oocyte fertilization rates.
  
  
  RESULTS
  Levels of MIS in FF and sera of PCOS patients were significantly higher than those in tubal factor patients: 7.01 +/- 1.52 versus 1.65 +/- 0.23 ng/mL (mean +/- SE) and 2.97 +/- 0.52 versus 0.92 +/- 0.19 ng/mL, respectively. In endometriosis patients, follicular fluid and serum MIS levels were not significantly different from those in tubal factor patients. In PCOS patients, the percentage of immature oocytes retrieved (17.9% +/- 5.0%) was significantly higher compared with tubal factor (1.5% +/- 1.0%) and endometriosis (9.2% +/- 2.3%) patients. The percentage of oocytes fertilize was significantly lower in PCOS patients (30.2% +/- 5.3%) compared with tubal factor (62.2% +/- 5.5%) and endometriosis (37.5% +/- 5.7%) patients.
  
  
  CONCLUSIONS
  Women with PCOS had higher serum and follicular fluid MIS levels, a higher percentage of immature oocytes, and lower fertilization rates than women with endometriosis or pelvic adhesions.
authors.affiliation: Department of Surgery, University of Louisville, USA.
authors.forename: M E
authors.initials: ME
authors.lastname: Fallat
authors.forename: Y
authors.initials: Y
authors.lastname: Siow
authors.forename: M
authors.initials: M
authors.lastname: Marra
authors.forename: C
authors.initials: C
authors.lastname: Cook
authors.forename: A
authors.initials: A
authors.lastname: Carrillo
mesh_terms: D000328:Adult; D054304:Anti-Mullerian Hormone; D004715:Endometriosis / Q000097:blood / Q000150:complications / Q000378:metabolism*; D005184:Fallopian Tube Diseases / Q000097:blood / Q000150:complications / Q000378:metabolism*; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use; D015571:Follicular Fluid / Q000378:metabolism*; D006023:Glycoproteins; D006131:Growth Inhibitors / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007247:Infertility, Female / Q000097:blood / Q000209:etiology / Q000378:metabolism*; D008596:Menotropins / Q000627:therapeutic use; D010062:Ovulation Induction; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications / Q000378:metabolism*; D011446:Prospective Studies; D013735:Testicular Hormones / Q000097:blood / Q000378:metabolism*
chemical_list: D006023:Glycoproteins; D006131:Growth Inhibitors; D013735:Testicular Hormones; D008596:Menotropins; D054304:Anti-Mullerian Hormone; D005640:Follicle Stimulating Hormone